Cardiac arrhythmias account for significant worldwide morbidity and mortality. Preventive antiarrhythmic therapies are aimed at modifying the abnormal electrophysiological substrate by either focal injury (surgery or radiofrequency catheter ablation) or pharmacological therapy. Antiarrhythmic drug therapy has been hampered by often low efficacy, global cardiac and systemic actions that often lead to poorly tolerated systemic side effects, and most important, life-threatening proarrhythmic effects. In this study, we present a novel combined cell and gene therapy approach for the modification of the myocardial electrophysiological substrate. Using fibroblast cell grafts genetically engineered to express specific potassium ionic channels, we aimed to perform a targeted modification of local cardiac electrophysiological properties. Detailed in vitro, in vivo, and computer modeling studies demonstrated the feasibility of this approach by showing that the engineered cells could couple with host cardiac cells and that this modified their electrophysiological properties. The cell grafts modulated important properties that are of interest for future antiarrhythmic strategies. These include prolongation of the local refractory period by a mechanism that does not involve action potential prolongation (potentially reducing the proarrhythmic risk associated with many antiarrhythmic agents that prolong the QT interval) and reduction in local automaticity (decreasing the spontaneous firing rate). See p 720.
Angiotensin II Receptor Blockade Reduces Tachycardia-Induced Atrial Adhesion Molecule Expression
Vascular thrombi develop in the presence of reduced blood velocities, when the activity of the clotting system is increased, and in the presence of endothelial alterations (Virchow's triad). Virchow's triad also applies to atrial thrombus formation during atrial fibrillation (AF). It is well known that AF causes loss of regular atrial contractions, and AF thereby reduces atrial blood flow velocities. Furthermore, AF is associated with activation of the plasmatic clotting system and of thrombocytes. However, the contribution of endothelial alterations to atrial thrombogenesis has not been fully explored. Increased endocardial expression of adhesion molecules (such as vascular cell adhesion molecule) could be an important link between initiation of inflammatory and prothrombogenic mechanisms responsible for thrombus development at the atrial endocardium ("endocardial remodeling"). The present study investigates the impact of AF on the expression of various prothrombotic atrial proteins in a large cohort of patients. The main finding of the study is an increased endocardial vascular cell adhesion molecule-1 expression in patients with AF. Interestingly, endocardial vascular cell adhesion molecule levels during AF are further increased by wellknown risk factors for thromboembolic events such as diabetes mellitus and heart failure. We can show that angiotensin II receptor blockers reduce tachycardia-induced atrial vascular cell adhesion molecule-1 expression ex vivo and in vivo, providing evidence that angiotensin II has a significant pathophysiological role in the prothrombogenic process of endocardial remodeling. Thus, the present study provides an important piece of information to explain the impact of angiotensin II receptor blockers on inflammatory and prothrombotic alterations at the atrial endocardium during AF. See p 732.
General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study
Cardiovascular disease (CVD) remains the leading cause of mortality and morbidity. A plethora of effective drugs for the major risk factors of CVD such as blood pressure, high cholesterol, and diabetes control exists. Prevention strategies assessing the risk of CVD and identifying the risk factors associated with the risk have become major approaches for reducing CVD and its unfavorable consequences. Presently, many of these strategies involve focusing on a component of CVD such as hard coronary disease consisting of myocardial infarction and coronary death, assessing the risk by mathematical risk functions or scoring functions, and designing treatment (behavioral and/or drug) according to the level of risk. Our belief is that, especially in the primary care setting, CVD risk should not be directed only to a component of CVD such as coronary disease or stroke but rather to all manifestation of CVD. In particular, individuals with high overall CVD risk require aggressive risk factor modification. In the present article, we present simple sex-specific risk functions that assess the 10-year risk (probability) of developing overall CVD. These functions involve inputs of blood pressure, cholesterol levels, diabetes, and smoking. Thus, not only is the overall risk quantified, but the source of the risk can be identified for treatment. Simple scoring sheets are presented that make the CVD functions immediately usable. Finally, straightforward adjustments to the functions can be used also to assess the risk for specific components of CVD. See p 743.
Dietary Intake and the Development of the Metabolic Syndrome: The Atherosclerosis Risk in Communities Study
Metabolic syndrome (MetSyn) is a cluster of cardiovascular disease risk factor abnormalities associated with increased risk of type 2 diabetes mellitus, cardiovascular disease, and all-cause mortality. The role of diet in the development of MetSyn is not well understood. In a prospective study of almost 15 000 middle-aged black and white adults, we observed a 13% to 18% higher risk of incident MetSyn among those eating a "Western diet" pattern, a diet characterized by high intakes of red and processed meat, fried food, regular soda, and refined-grain products and low intakes of fruit and vegetables, fish, and whole-grain products. To support this result, we found that eating 1 to 2 servings per day of meat was associated with 17% to 26% higher risk of incident MetSyn compared with onefourth serving per day, and eating fried foods everyday also was associated with higher risk. Risk of MetSyn was lower among adults consuming Ͼ3 daily servings of dairy products compared with one-fourth serving. Interestingly, adults who consumed 1 serving of diet soda a day had a 34% higher risk of MetSyn compared with nonconsumers. These prospective findings suggest that consumption of a Western dietary pattern, meat, and fried foods promotes the incidence of MetSyn, whereas dairy consumption provides some protection. The diet soda association was not hypothesized and deserves further study. See p 754.
Identification of Target Domains of the Cardiac Ryanodine Receptor to Correct Channel Disorder in Failing Hearts
A considerable body of evidence shows that the defective operation of the sarcoplasmic reticulum Ca 2ϩ release channel, also known as 711
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Original Research Put Into Perspective for the Practicing Clinician Volume 117 Ⅲ Number 6 Ⅲ February 12, 2008 ryanodine receptor 2 (RyR2), is a major causative factor of heart failure. Previously, we demonstrated that an interdomain interaction within RyR2, which stabilizes the channel gating, is defective in failing hearts, resulting in Ca 2ϩ leak and contractile dysfunction. We have also shown that K201 (also known as JTV519) reversed the mode of interdomain interaction from a defective unzipped configuration to a normal zipped configuration and stopped Ca 2ϩ leak. In this article, the mechanism by which K201 corrects the channel disorder of RyR2 is defined. The specific binding site of K201 was found to reside in the central domain of RyR2. The binding of K201 to this domain interferes with an interdomain interaction between the RyR2 drug-binding domain (2114 to 2149) and its partner domain. The specific interruption of this interdomain interaction within RyR2 seems to play a critical role in stabilizing the channel gating. These results further support the notion that fixing the defective interdomain interaction within RyR2 is a promising therapeutic strategy for treatment of heart failure. See p 762.
Adenosine Modulates Cardiovascular Functions Through Activation of Extracellular Signal-Regulated Kinases 1 and 2 and Endothelial Nitric Oxide Synthase in the Nucleus Tractus Solitarii of Rats
The sympathetic nervous system has moved toward center stage in cardiovascular medicine. Studies have demonstrated that sympathetic overactivity characterizes the hypertensive state and participates in the development, maintenance, and progression of elevated blood pressure. The importance of sympathetic overactivity in heart failure progression and mortality and in the generation of ventricular arrhythmias is now well established, and a central nervous systemmean arterial pressure (CNS-MAP) set-point theory has recently been proposed. It has been hypothesized that hypertension occurs as the result of a primary shift of the CNS-MAP set point to a higher operating pressure, which results in increased sympathetic nerve activity. The nucleus tractus solitarius (NTS), located at the dorsal part of the brainstem, was discovered to be an important sympathetic nervous system integral center in the central nervous system. Adenosine, a ubiquitously distributed neuromodulator, was found to participate in sympathetic activity regulation in the NTS. In the present study, we investigated the signaling mechanism of adenosine with regard to cardiovascular modulation in the NTS and found that the MEK-ERK (mitogen-activated protein kinase-extracellular signal-regulated kinase) cascade, which was originally discovered to be a critical regulator of cell division and differentiation, participates in adenosine-mediated central cardiovascular control. In addition, we also demonstrated that endothelial nitric oxide synthase, which was originally identified in the vascular endothelium, is present and participates in cardiovascular regulation in the NTS. Further investigation of the molecular mechanisms involved in sympathetic nervous activity modulation might elucidate the pathogenesis of the CNS-MAP set-point shift and sympathetic overactivity in essential hypertension. See p 773.
Technetium 99m-Labeled Annexin V Scintigraphy of Platelet Activation in Vegetations of Experimental Endocarditis
The mural thrombus, whatever its location (vascular, intracardiac, or valvular), exhibits biological activity (proaggregant and fibrinolytic) because of the maintenance of a dynamic interface with the circulating blood. Experimental thrombotic endocarditis is a model of mural thrombus, in which biological activity is enhanced by bacterial colonization. Binding of bacteria to platelets can induce their activation and aggregation, resulting in phosphatidylserine exposure.
Annexin V specifically binds with nanomolar affinity to phosphatidylserines. This preclinical study shows the ability of radiolabeled annexin V to provide in vivo functional imaging of platelet activation in experimental endocarditis. Annexin V uptake was predominant in the luminal layer of the vegetation, at the interface with circulating blood, and its uptake was enhanced by bacterial colonization of the vegetation. As suggested by previous preclinical studies of atherothrombosis or abdominal aortic aneurysm models, radiolabeled annexin V is able to provide insight into platelet activation in various degenerative cardiovascular diseases. Additionally, radiolabeled annexin V allowed the detection of pulmonary emboli in right-sided endocarditis. The embolic potential of vegetations is related to their fibrinolytic activity and is a prognostic determinant in human endocarditis. Indeed, the incidence of emboli was high when the infective pathogen was Staphylococcus aureus, a bacterium known to interact with the plasminergic system of the host. In this regard, tracers targeting fibrinolytic activity would be of interest. Finally, the detection of phlebothrombosis associated with silicone rubber catheters, close to human pacemaker leads, suggests a potential role of radiolabeled annexin V in the diagnosis of implantable cardiac device infection. See p 781.
Saphenous Vein Graft Stenting and Major Adverse Cardiac Events: A Predictive Model Derived From a Pooled Analysis of 3958 Patients
Saphenous vein graft percutaneous coronary intervention carries with it a high risk of major adverse cardiac events, particularly periprocedural myocardial infarction. The short-term risk approaches 20%, and before the introduction of embolic protection devices, no adjunctive therapy had been shown to reduce this risk. Despite accumulating evidence from randomized trials suggesting consistent reductions in the rate of 30-day major adverse cardiac events with the use of embolic protection devices by Ϸ40%, it is estimated that these devices are used in only half of saphenous vein graft interventions. Our analysis, which pooled 3958 patients enrolled in 5 randomized, controlled trials and 1 registry of embolic protection devices, identified 2 angiographic measures of plaque burden, plaque volume and a graft degeneration score, as the most important independent predictors of 30-day major adverse cardiac events. Additional independent clinical risk factors included increasing patient age and tobacco use. Saphenous vein graft percutaneous coronary intervention consistently provided embolic protection in reducing 30-day major adverse cardiac events across the broad range of characteristics in patients tested in randomized trials. The reliability of the model developed across patients and trials suggests that new embolic protection device safety and efficacy could be evaluated in the future against risk-adjusted models of expected rates of adverse events. This could facilitate evaluation of new embolic protection devices and their adoption to prevent adverse events. See p 790.
Visceral Adipose Tissue Inflammation Accelerates Atherosclerosis in Apolipoprotein E-Deficient Mice
The epidemic of obesity will promote morbidity and mortality resulting from cardiovascular diseases in the next few decades. Links between obesity and vascular risk remain to be elucidated; however, several recent clinical studies have suggested that visceral adiposity is largely responsible for obesity-associated vascular risk. Whether visceral adipose tissue is a marker or mediator of vascular risk is unclear. Experimental models of obesity have demonstrated marked differences between visceral and subcutaneous fat in terms of adipocytokine expression and leukocyte infiltration. The multiple metabolic changes associated with states of generalized obesity confound efforts to establish a causal link between fat tissue and vascular end points. Here, we used a model of fat transplantation, which is associated with inflammation in the transplanted fat depot, to examine the effect of inflammatory fat on atherosclerosis. In the absence of generalized obesity or diabetes, we found that transplanted visceral fat is capable of promoting atherosclerosis in mice. This effect on atherosclerosis was not observed when subcutaneous fat was transplanted, despite a similar degree of macrophage infiltration into the transplanted fat depot. The specific factors responsible for the effect of inflammatory visceral fat on atherosclerosis remain to be identified, although plasma monocyte chemoattractant protein-1 levels were higher in mice with visceral compared with subcutaneous fat transplants. Treatment of mice with the peroxisome proliferator-activated receptor-␥ ligand pioglitazone reduced monocyte chemoattractant protein-1, fat inflammation, and atherosclerosis induced by the visceral fat transplant. Interventions that target inflammation within visceral fat may be useful in reducing the vascular risk associated with central obesity. See p 798.
Remodeling Phenotype of Human Subcutaneous Adipose Tissue Macrophages
Obesity is characterized by a systemic low-grade inflammatory state that is thought to contribute to the genesis of obesity-associated cardiovascular diseases and type 2 diabetes mellitus. However, the cellular and molecular mechanisms underlying the link between fat mass enlargement, inflammation, and obesity-associated pathologies remain to be clearly defined. Adipose tissue (AT) itself produces a wide range of adipokines with inflammatory properties, and its excessive development has been associated in humans and mice with accumulation of AT macrophages (ATMs). The present study, performed in subcutaneous ATs from lean to overweight individuals, showed that ATMs coexpressed proinflammatory and antiinflammatory factors. Furthermore, ATMs specifically produced and released the key matrix remodeling enzyme matrix metalloproteinase-9 compared with mature adipocytes and AT capillary endothelial cells. Interestingly, the secretion of matrix metalloproteinase-9 from human AT in vivo, assessed by arteriovenous difference measurement, was correlated with the body mass index of the patients. An increase in body mass index also was found to be associated in ATMs with lower expression levels of 2 proinflammatory factors (ie, interleukin-8 and cyclooxygenase-2) and a higher expression level of the remodeling marker lymphatic vessel endothelial hyaluronan receptor-1. Finally, ATMs exerted marked in vitro proangiogenic effects on AT-derived capillary endothelial and progenitor cells. These overall results indicate that the human ATMs that accumulate within the fat mass during its growth exhibit a particular remodeling phenotype. ATMs may thus be active players in AT development via their proangiogenic effects but also in the genesis of obesityassociated cardiovascular pathologies through their release of matrix metalloproteinase-9. See p 806.
Oral Buflomedil in the Prevention of Cardiovascular Events in Patients With Peripheral Arterial Obstructive Disease: A Randomized, Placebo-Controlled, 4-Year Study
Cardiovascular-related morbidity and mortality in patients with peripheral arterial obstructive disease remain high. Buflomedil is an ␣ 1 -, ␣ 2 -adrenolytic agent with vasoactive and hemorheologic properties. An international, multicenter, randomized, double-blind, placebo-controlled trial was performed to investigate whether longterm administration of buflomedil would reduce the occurrence of critical cardiovascular events and prevent the worsening of clinical symptoms in patients Ͼ40 years of age with peripheral arterial obstructive disease, intermittent claudication, and an ankle-brachial index between 0.30 and 0.80. Aspirin was recommended for all patients. The primary efficacy outcome was critical cardiovascular events, defined as the composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, symptomatic deterioration of peripheral arterial obstructive disease, or leg amputation. A total of 2078 patients were recruited. Mean treatment duration was 33 months. The rate of the primary outcome was significantly lower in buflomedil-randomized patients than in placebo-randomized patients (9.1% versus 12.4%; hazard ratio, 0.742; 95% confidence interval, 0.603 to 0.915; Pϭ0.0163). Although not significantly, the event rate of each of the components of the primary efficacy outcome was reduced in buflomedil-randomized patients. Concerning major clinical events, including total death and surgical treatment of peripheral arterial obstructive disease (amputation, vascular surgery, or angioplasty on the lower limbs), the trend in favor of buflomedil was particularly clear. Tolerance of buflomedil and placebo was comparable. Compared with placebo, buflomedil administered for 3 years reduced the occurrence of symptomatic cardiovascular events by 26%, the main contributor to the difference in the composite outcome being the reduction of symptomatic deterioration of peripheral arterial disease. This amplitude of risk reduction was comparable to that observed with other effective drugs classically administered in this indication. Therefore, the use of buflomedil should be considered in addition to an antiplatelet agent in patients with peripheral arterial obstructive disease and intermittent claudication. See p 816.
Symptomatic Peripheral Arterial Disease in Women: Nontraditional Biomarkers of Elevated Risk
Lower-extremity peripheral arterial disease (PAD) is an underrecognized manifestation of atherosclerosis warranting greater attention in both clinical research and clinical practice. Far less information has been available about risk factors for PAD than for coronary or cerebrovascular disease, especially among women. Although established cardiovascular risk factors such as smoking, diabetes, hypertension, and dyslipidemia also are clinical predictors of PAD, few prospective studies have evaluated the role of novel or emerging risk factors such as subclinical inflammation, thrombosis, and endothelial dysfunction. This study is the first prospective analysis of PAD in women to provide comparative data for a broad range of more commonly evaluated novel biomarkers against each other, markers of dysglycemia, renal dysfunction, and conventional lipid levels. Biomarkers assessed included high-sensitivity C-reactive protein, fibrinogen, soluble intercellular adhesion molecule-1, homocysteine, lipoprotein(a), hemoglobin A 1c , creatinine, creatinine clearance, and standard lipid parameters. In this large population of initially healthy women Ն45 years of age without prior vascular disease, only 4 factors, soluble intercellular adhesion molecule-1, high-sensitivity C-reactive protein, high-density lipoprotein, and ratio of total cholesterol to high-density lipoprotein cholesterol, were associated with the incidence of symptomatic PAD. The strongest association was noted for soluble intercellular adhesion molecule-1 (adjusted hazard ratio extreme tertiles, 4.0; 95% confidence interval, 1.9 to 8.6; P for trend Ͻ0.001). Increased levels of this proinflammatory cellular adhesion molecule reflect endothelial activation and leukocyte recruitment. Interestingly, prior data from both this cohort and other populations have shown only modest associations of soluble intercellular adhesion molecule-1 with coronary or cerebrovascular disease. The current results thus support the concept that factors predisposing to plaque rupture as manifested by acute coronary events differ from those causing more gradual luminal obstruction as in the pathogenesis of PAD. See p 823.
